Review
Copyright ©The Author(s) 2015.
World J Diabetes. Jun 25, 2015; 6(6): 792-806
Published online Jun 25, 2015. doi: 10.4239/wjd.v6.i6.792
Table 1 Relevant features of the most common imaging modalities
Imaging modalityAnatomyMetabolism/ functionSpatial resolutionWeakness
SPECTPoorYes0.3-3 mmRadiation
PETPoorYes1-4 mmRadiation
CTYesYes0.5-1 mmRadiation
MRIYesYes50-500 μmExpensive
UltrasoundYesYesApproximately 200 μmPoor depth penetration
OpticalPoorYes0.1-10 mmPoor depth penetration
Table 2 Main nuclides used in nuclear medicine to label radiopharmaceuticals
SPECT
PET
NuclideHalf-lifeγ (KeV%)NuclideHalf-lifeβ+ (KeV%)
99mTc6.02 h8918F109.8 min96.9
111In2.83 d90.211C20.4 min99.7
123I13.2 h8313N9.98 min99.8
125I60.14 d6.515O2.03 min99.9
124I4.18 d25.0
64Cu12.7 h17.9
68Ga68 min90.0
82Rb1.2 min99.9
Table 3 Synopsis of imaging modalities and their applications in diabetes
SPECT/PETCTMRUSOpticalApplication
Pancreas (β-cell function)[18F]-tracerMRILuminescenceMainly preclinical[61,62]
Pancreas (transplant/ inflammation)[18F]-tracerMRIHigh-frequencyPreclinical and clinical[63-68]
KidneyMRI/BOLD-MRIB-mode/DopplerClinical[70-78]
Brain[123I]- and [99Tc]-tracerMRI/MRSDopplerClinical[22,82,83]
Vessels/atherosclerosis[18F]-tracerAngio-CTMRIB-modeClinical[85-95,100-106]
Ulcerations[99Tc]-tracerHybrid SPECT/CTMRIDopplerHISClinical[113,114,116,117]
Heart[18F]-, [123I]- [11C]-tracerHybrid PET/CTMRI/MRSDopplerClinical[95,120-126,130,131,134,135]
Visceral fatCT/dual energy CTMRI/MRSB-modeClinical[142,145,146]